Skip to main content
Contact Us
Subscribe
E-Edition
56°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aprea Therapeutics Inc
(NQ:
APRE
)
2.540
UNCHANGED
Streaming Delayed Price
Updated: 3:12 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Aprea Therapeutics Inc
< Previous
1
2
3
4
Next >
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 12, 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
May 14, 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 04, 2024
Via
Benzinga
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 26, 2024
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Aprea Therapeutics: Q4 Earnings Insights
March 26, 2024
Via
Benzinga
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
March 11, 2024
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 11, 2024
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
October 30, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
September 25, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
September 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 18, 2023
Via
Benzinga
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
June 09, 2023
The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 07, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
April 03, 2023
On Monday, 76 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
March 10, 2023
Via
Benzinga
Why Aprea Therapeutics Shares Hit A New 52-Week Low Today
February 23, 2023
Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else?
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 11, 2023
Via
Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 05, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 07, 2022
Via
Benzinga
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
December 05, 2022
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 11, 2022
Gainers
Via
Benzinga
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
November 14, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
Via
Benzinga
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
November 11, 2022
Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $5 million share repurchase program.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 13, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
November 11, 2022
On Friday, 63 stocks hit new 52-week lows.
Via
Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.